GLPwatch

Prevent and Reverse Obesity in Children, Adolescents and Young Adults

NCT07035704 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests a weight management program in children, adolescents, and young adults who are overweight to see how it affects their body weight.

Status Not yet recruiting Approved but enrollment has not started.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) study
Participants 200 people Planned (estimated).
Who can join Ages 18–55 · all sexes Healthy volunteers accepted.
Timeline Started 2025-09 · est. completion 2027-03
Where 1 site · Italy

What this study is testing ClinicalTrials.gov NCT07035704 ↗

Description as written by the study sponsor.

Obesity and overweight are non-communicable diseases with an increasing incidence in children, adolescents, and adults. International efforts to reverse the current epidemiological trend of rising overweight, obesity, and related diseases have so far been insufficient to achieve this goal. Therefore, a change in strategy-both at the individual and public health levels-is urgently needed. Searching the litterature, there are currently no studies employing a comprehensive, personalized, and multi-level strategy to induce stable changes in dietary and lifestyle habits, while also conducting careful follow-up of outcomes and exploring the pathogenic mechanisms affecting metabolic pathways, pro-inflammatory and systemic conditions, and intestinal permeability in overweight and obese patients. Evidence shows the beneficial effects of specific dietary patterns (e.g., the Mediterranean Diet) and a healthy lifestyle in reducing body/organ fat accumulation. However, a comprehensive evaluation of their effects-particularly following personalized strategies and careful follow-up-on the pathogenic mechanisms influencing cardiovascular and metabolic risk, pro-inflammatory status, and intestinal permeability in the medium-to-long term is still lacking.

Treatments tested

Main thing measuredWeight (Kg)
Sponsorpiero portincasa
Conditions studiedOverweight (BMI > 25)
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07035704 ↗